{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:18Z","timestamp":1787027778492,"version":"build-2736575974"},"reference-count":46,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["VU2010-4809"],"award-info":[{"award-number":["VU2010-4809"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Epstein-Barr virus (EBV) persists in nasopharyngeal (NPC) and gastric carcinomas (EBVaGC) in a tightly latent form. Cytolytic virus activation (CLVA) therapy employs gemcitabine and valproic acid (GCb+VPA) to reactivate latent EBV into the lytic phase and antiviral valganciclovir to enhance cell death and prevent virus production. CLVA treatment has proven safe in phase-I\/II trials with promising clinical responses in patients with recurrent NPC. However, a major challenge is to maximize EBV lytic reactivation by CLVA. Curcumin, a dietary spice used in Asian countries, is known for its antitumor property and therapeutic potential. Novel curcuminoids that were developed to increase efficacy and bioavailability may serve as oral CLVA adjuvants. We investigated the potential of curcumin and its analogs (curcuminoids) to trigger the EBV lytic cycle in EBVaGC and NPC cells. EBV-reactivating effects were measured by immunoblot and immunofluorescence using monoclonal antibodies specific for EBV lytic proteins. Two of the hit compounds (41, EF24) with high lytic inducing activity were further studied for their synergistic or antagonistic effects when combined with GCb+VPA and analyzed by cytotoxicity and mRNA profiling assays to measure the EBV reactivation. Curcuminoid as a single agent significantly induced EBV reactivation in recombinant GC and NPC lines. The drug effects were dose- and time-dependent. Micromolar concentration of curcuminoid EF24 enhanced the CLVA effect in all cell systems except SNU719, a naturally infected EBVaGC cell that carries a more tightly latent viral genome. These findings indicated that EF24 has potential as EBV lytic activator and may serve as an adjuvant in CLVA treatment.<\/jats:p>","DOI":"10.3390\/cancers10040089","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T09:12:11Z","timestamp":1521709931000},"page":"89","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas"],"prefix":"10.3390","volume":"10","author":[{"given":"Octavia","family":"Ramayanti","sequence":"first","affiliation":[{"name":"Department of Pathology, VU University Medical Center, 1081HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Brinkkemper","sequence":"additional","affiliation":[{"name":"Department of Pathology, VU University Medical Center, 1081HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Verkuijlen","sequence":"additional","affiliation":[{"name":"Department of Pathology, VU University Medical Center, 1081HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leni","family":"Ritmaleni","sequence":"additional","affiliation":[{"name":"Laboratory of Medicinal Chemistry, Gadjah Mada University, Yogyakarta 55281, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Go","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National University of Singapore, Singapore 117543, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0765-4125","authenticated-orcid":false,"given":"Jaap","family":"Middeldorp","sequence":"additional","affiliation":[{"name":"Department of Pathology, VU University Medical Center, 1081HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tim.2016.03.008","article-title":"Viral carcinogenesis beyond malignant transformation: EBV in the progression of human cancers","volume":"24","author":"Pagano","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_2","unstructured":"Niller, H.H., Banati, F., and Minarovits, J. (2014). Epigenetic alterations in nasopharyngeal carcinoma and Epstein-Barr virus (EBV) associated gastric carcinoma: A lesson in contrasts. J. Nasopharyngeal Carcinoma, 1."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000434683","article-title":"Epstein-Barr virus-associated gastric carcinoma: Use of host cell machineries and somatic gene mutations","volume":"82","author":"Abe","year":"2015","journal-title":"Pathobiology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ghosh, S.K., Perrine, S.P., and Faller, D.V. (2012). Advances in virus-directed therapeutics against Epstein-Barr Virus-associated malignancies. Adv. Virol., 2012.","DOI":"10.1155\/2012\/509296"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2147\/TCRM.S47434","article-title":"Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma","volume":"10","author":"Hutajulu","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/1078-0432.CCR-12-0574","article-title":"Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors","volume":"18","author":"Wildeman","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00432-015-1969-3","article-title":"Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma","volume":"141","author":"Stoker","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_8","first-page":"237","article-title":"Epstein-Barr virus lytic cycle reactivation","volume":"391","author":"McKenzie","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_9","first-page":"449","article-title":"Agents and approaches for lytic induction therapy of Epstein-Barr Virus associated malignancies","volume":"6","author":"Novalic","year":"2016","journal-title":"Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.cellbi.2008.03.022","article-title":"NF-\u03baB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells","volume":"32","author":"Liu","year":"2008","journal-title":"Cell Biol. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1021\/cb4006326","article-title":"Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr virus","volume":"9","author":"Tikhmyanova","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Choi, C.K., Ho, D.N., Hui, K.F., Kao, R.Y., and Chiang, A.K.S. (2015). Identification of novel small organic compounds with diverse structures for the induction of Epstein-Barr virus (EBV) lytic cycle in EBV-positive epithelial malignancies. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145994"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00018-008-7452-4","article-title":"Curcumin: From ancient medicine to current clinical trials","volume":"65","author":"Hatcher","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1476-4598-10-12","article-title":"Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma","volume":"10","author":"Wilken","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3727\/096504015X14452563486011","article-title":"Curcumin Enhances the Effects of 5-Fluorouracil and Oxaliplatin in Inducing Gastric Cancer Cell Apoptosis Both In Vitro and In Vivo","volume":"23","author":"Zhou","year":"2016","journal-title":"Oncol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.3892\/ijo.2016.3425","article-title":"A novel curcuminoid exhibits enhanced antitumor activity in nasopharyngeal carcinoma","volume":"48","author":"Pan","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/cmdc.201200293","article-title":"Curcuminoids with potent and selective anti-proliferative activity on acute promyelocytic leukemia: Involvement of accumulated misfolded nuclear receptor co-repressor (N-CoR) protein as a basis for selective activity","volume":"7","author":"Tan","year":"2012","journal-title":"Chem. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1021\/jm401352a","article-title":"Synthesis and evaluation of bisbenzylidenedioxotetrahydrothiopranones as activators of endoplasmic reticulum (ER) stress signaling pathways and apoptotic cell death in acute promyelocytic leukemic cells","volume":"57","author":"Tan","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0223-5234(97)83288-6","article-title":"1,5-Diphenyl-1,4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship","volume":"32","author":"Sardjiman","year":"1997","journal-title":"Eur. J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7314\/APJCP.2014.15.1.179","article-title":"Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-\u03baB activation","volume":"15","author":"Putri","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18050","DOI":"10.18632\/oncotarget.7633","article-title":"EF24 induces ROS-mediated apoptosis via targeting thioredoxin reductase 1 in gastric cancer cells","volume":"7","author":"Zou","year":"2016","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1124\/mol.108.046201","article-title":"Inhibition of I\u03baB Kinase-Nuclear Factor-\u03baB Signaling Pathway by 3,5-Bis(2-flurobenzylidene) piperidin-4-one (EF24), a Novel Monoketone Analog of Curcumin","volume":"74","author":"Kasinski","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yang, C.H., Yue, C., Sims, M., and Pfeffer, L.M. (2013). The curcumin analog EF24 targets NF-\u03baB and miRNA-21 and has potent anticancer activity in vitro and in vivo. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071130"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/ijc.27439","article-title":"Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid hits to apoptosis and tumor growth suppression of nasopharyngeal carcinoma","volume":"131","author":"Hui","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.canlet.2016.04.001","article-title":"Cordycepin enhances Epstein-Barr virus lytic infection and Epstein-Barr virus-positive tumor treatment efficacy by doxorubicin","volume":"376","author":"Du","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1158\/1078-0432.CCR-12-2537","article-title":"hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: A basis for new therapies","volume":"19","author":"Giunco","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10515","DOI":"10.1128\/JVI.00955-13","article-title":"Epstein-Barr virus-encoded BARF1 promotes proliferation of gastric carcinoma cells through regulation of NF-\u03baB","volume":"87","author":"Chang","year":"2013","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/ijc.24945","article-title":"Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death","volume":"126","author":"Hui","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1128\/JVI.00315-08","article-title":"The Epstein-Barr virus LF2 protein inhibits viral replication","volume":"82","author":"Calderwood","year":"2008","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jviromet.2016.12.007","article-title":"Quantitative multi-target RNA profiling in Epstein-Barr virus infected tumor cells","volume":"241","author":"Greijer","year":"2017","journal-title":"J. Virol. Methods"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1128\/JVI.01437-14","article-title":"Role of ATM in the formation of the replication compartment during lytic replication of Epstein-Barr virus in nasopharyngeal epithelial cells","volume":"89","author":"Hau","year":"2015","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ijc.30418","article-title":"Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin","volume":"140","author":"Ramayanti","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10641","DOI":"10.1128\/JVI.01178-13","article-title":"Activation of human herpesvirus replication by apoptosis","volume":"87","author":"Prasad","year":"2013","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Liu, H., Liang, Y., Wang, L., Tian, L., Song, R., Han, T., Pan, S., and Liu, L. (2012). In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcuminoid. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048075"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1128\/JVI.00013-12","article-title":"Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection","volume":"86","author":"Sivachandran","year":"2012","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bbrc.2016.04.070","article-title":"Epstein-Barr virus latency type and spontaneous reactivation predict lytic induction levels","volume":"474","author":"Phan","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.virol.2003.12.005","article-title":"A naturally derived gastric cancer cell line shows latency I Epstein-Barr virus infection closely resembling EBV-associated gastric cancer","volume":"320","author":"Oh","year":"2004","journal-title":"Virology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12275-015-4672-9","article-title":"Genipin as a novel chemical activator of EBV lytic cycle","volume":"53","author":"Son","year":"2015","journal-title":"J. Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.antiviral.2012.09.003","article-title":"Resveratrol inhibits Epstein Barr Virus lytic cycle in Burkitt\u2019s lymphoma cells by affecting multiple molecular targets","volume":"96","author":"Arena","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/mc.21926","article-title":"Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane","volume":"52","author":"Wu","year":"2013","journal-title":"Mol. Carcinog."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.antiviral.2016.05.007","article-title":"Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes","volume":"132","author":"Wu","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.virol.2014.10.030","article-title":"Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA","volume":"474","author":"Tierney","year":"2015","journal-title":"Virology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ijc.29698","article-title":"Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir","volume":"138","author":"Hui","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-012-2017-5","article-title":"In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation","volume":"71","author":"Hao","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/1535-7163.MCT-12-0654","article-title":"Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts","volume":"12","author":"Pratt","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wildeman, M.A., Fles, R., Herdini, C., Indrasari, R.S., Vincent, A.D., Tjokronagoro, M., Stoker, S., Kurnianda, J., Karakullukcu, B., and Taroeno-Hariadi, K.W. (2013). Primary treatment results of Nasopharyngeal Carcinoma (NPC) in Yogyakarta, Indonesia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063706"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/4\/89\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:58:07Z","timestamp":1760194687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/4\/89"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4]]}},"alternative-id":["cancers10040089"],"URL":"https:\/\/doi.org\/10.3390\/cancers10040089","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]}}}